Stocktoria
Telomir Pharmaceuticals, Inc. TELO
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2024-02-09
Telomir Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D expense | $2.4M | $2.2M | $1.6M | $833,206 |
| Interest expense | — | — | $1.6M | — |
| Net income | -$10.4M | -$16.5M | -$13.1M | -$854,147 |
| EPS (diluted) | $-0.33 | $-0.56 | $0.48 | $-0.03 |
| Operating cash flow | -$3.7M | -$5.1M | -$3.9M | -$468,661 |
| Cash & equivalents | — | $1.3M | — | — |
| Total assets | $7.3M | $1.3M | $4.8M | $48,730 |
| Total liabilities | $1.4M | $680,968 | $1.3M | $986,008 |
| Shareholders' equity | $5.9M | $643,037 | $3.4M | -$937,278 |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| EPS growth | — | -216.7% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.